SynthesisScientific reports2016
The Prognostic Value of PLR in Lung Cancer, a Meta-analysis Based on Results from a Large Consecutive Cohort.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Prognostic value of platelet-to-lymphocyte ratio in patients with oral squamous cell carcinoma: a systematic review and meta-analysis.BMC oral health · 2024Pooled it
- The Prognostic Value of Platelet-to-Lymphocyte Ratio in Urological Cancers: A Meta-Analysis.Scientific reports · 2017Pooled it
- Prognostic nutritional index as a prognostic biomarker for survival in digestive system carcinomas.Oncotarget · 2016Pooled it
- Trial
- Inflammation-based hematologic indices and overall survival in poorly differentiated thyroid carcinoma: a retrospective exploratory study.Langenbeck's archives of surgery · 2026Article
- Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers.Current oncology (Toronto, Ont.) · 2026Article
- Association of neutrophil percentage-to-albumin ratio with distant metastasis and survival outcomes in breast cancer patients: a retrospective and prospective cohort study.Scientific reports · 2025Article
- Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.Thoracic cancer · 2025Article
- Association between airway microbiota and systemic inflammation markers in non-small cell lung cancer patients.Scientific reports · 2025Article
- Complete blood count parameters as potential predictive factors of brain metastases in lung cancer.Frontiers in oncology · 2025Article
- Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in lung carcinoid patients after receiving curative surgery. A multicentre study.Frontiers in oncology · 2025Article
- Postoperative short-term prognostic factors in patients with primary lung cancer who undergo lobectomy: a study on the prognostic predictors of early postoperative recurrence.Journal of thoracic disease · 2024Article
- Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations.Discover oncology · 2024Article
- Using the combined C-reactive protein and controlling nutritional status index for elderly non-small cell lung cancer.Journal of thoracic disease · 2024Article
- Exploring Inflammatory Parameters in Lung Cancer Patients: A Retrospective Analysis.Journal of personalized medicine · 2024Article
- Review
- A study of pre- and post-treatment hematologic markers of immune response in patients undergoing radiotherapy for soft tissue sarcoma.Frontiers in oncology · 2024Article
- Circulomic variables predict pathologic staging preoperatively in treatment-naïve non-small cell lung cancer.Journal of thoracic disease · 2023Article
- Article
- IRAK2, an Immune and Radiation-Response Gene, Correlates with Advanced Disease Features but Predicts Higher Post-Irradiation Local Control in Non-Metastatic and Resected Oral Cancer Patients.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, many studies have been conducted to explore prognostic value of platelet to lymphocyte ratio (PLR) for patients with lung cancer, while the results remain controversial. We collected pretreatment, clinicopathological and follow-up data of 1388 lung cancer patients receiving surgery between 2006 and 2011 in our hospital, and reviewed relevant articles from Embase, Pubmed, Web of science databases, then performed a meta-analysis to clarify the relationship between PLR and prognosis of lung cancer patients. Finally, 11 articles with our study were included, results indicated elevated PLR was negatively related to overall survival (HR = 1.33, 95% CI: 1.10-1.62), but not related to progress-free survival (HR = 1.21, 95% CI: 0.97-1.49). Subgroup analysis suggested high PLR was correlated with poor survival in non-small cell lung cancer (HR = 1.43, 95% CI: 1.14-1.78), but not in small cell lung cancer (HR = 1.10, 95% CI: 0.76-1.58). Besides, for patients treated by chemotherapy or radiotherapy (HR = 1.66, 95% CI: 1.15-2.38) and patients in late stage (HR = 1.41, 95% CI: 1.19-1.68), PLR had significantly prognostic value. Additionally, the result was significant for patients when cut-off value of PLR was between 150 and 200 (HR = 1.47, 95% CI: 1.18-1.82). In Conclusion, this meta-analysis revealed that elevated PLR was associated with poor prognosis in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.